Evidence map›Paper›PMID 22547331›Full record

Trial reportPsychopharmacology2012

Varenicline decreases alcohol consumption in heavy-drinking smokers.

Jennifer M Mitchell, Candice H Teague, Andrew S Kayser, Selena E Bartlett, Howard L Fields

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01011907 (Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence), which is not on this map. Cited by 98 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 6 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01011907 nacompletednot on this map

Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2012Enrolled99ConditionsSubstance DependenceArmsvarenicline, placebo
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 6 syntheses or guidelines pooled it, 179 citations in OpenAlex.

  1. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023
    Pooled it
  2. Pooled it
  3. Efficacy of Varenicline in the Treatment of Alcohol Dependence: An Updated Meta-Analysis and Meta-Regression.International journal of environmental research and public health · 2023
    Pooled it
  4. Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2016
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Alcohol use disorder severity moderates clinical response to varenicline.Alcoholism, clinical and experimental research · 2021
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jennifer M MitchellErnest Gallo Clinic and Research Center, University of California, San Francisco, 5858 Horton Street, Suite #200, Emeryville, CA 94608, USA. jmitchell@gallo.ucsf.edu
Candice H Teague
Andrew S Kayser
Selena E Bartlett
Howard L Fields
University of California, San Francisco · USErnest Gallo Clinic and Research Center · US

Funding

Characterizing Alpha5* Nicotinic Receptors in Alcohol and Nicotine Co-DependenceRC2AA019429 · NIAAA · ERNEST GALLO CLINIC AND RESEARCH CENTER · PI BARTLETT, SELENA E., WHITE, RAYMOND L · 2009 to 2010
$2.0M
NIAAA NIH HHS AA019429-01NIAAA NIH HHS RC2 AA019429
6 · The paper itself

Abstract

rationaleEmerging evidence suggests that the α4β2 form of the nicotinic acetylcholine receptor (nAChR) modulates the rewarding effects of alcohol. The nAChR α4β2 subunit partial agonist varenicline (Chantix™), which is approved by the Food and Drug Administration for smoking cessation, also decreases ethanol consumption in rodents (Steensland et al., Proc Natl Acad Sci U S A 104:12518-12523, 2007) and in human laboratory and open-label studies (Fucito et al., Psychopharmacology (Berl) 215:655-663, 2011; McKee et al., Biol Psychiatry 66:185-190 2009).

objectivesWe present a randomized, double-blind, 16-week study in heavy-drinking smokers (n = 64 randomized to treatment) who were seeking treatment for their smoking. The study was designed to determine the effects of varenicline on alcohol craving and consumption. Outcome measures included number of alcoholic drinks per week, cigarettes per week, amount of alcohol craving per week, cumulative cigarettes and alcoholic drinks consumed during the treatment period, number of abstinent days, and weekly percentage of positive ethyl glucuronide and cotinine screens.

resultsVarenicline significantly decreases alcohol consumption (χ (2) = 35.32, p < 0.0001) in smokers. Although varenicline has previously been associated with suicidality and depression, side effects were low in this study and declined over time in the varenicline treatment group.

conclusionsVarenicline can produce a sustained decrease in alcohol consumption in individuals who also smoke. Further studies are warranted to assess varenicline efficacy in treatment-seeking alcohol abusers who do not smoke and to ascertain the relationship between varenicline effects on smoking and drinking.

Indexed as

AdultAlcohol DrinkingAlcoholismBenzazepinesDouble-Blind MethodDrug Administration ScheduleFemaleHealth Records, PersonalHumansMaleMiddle AgedNicotinic AgonistsQuinoxalinesSmokingSmoking CessationTreatment OutcomeBenzazepinesNicotinic AgonistsQuinoxalinesVarenicline

Identifiers

PMID22547331
PMCPMC3438402
OpenAlexW1993563487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.